Interim Report 1 July – 30 September 2021
- Strategy updated to include two products targeting 510(k)-approval
- Published data from first comparative study and first study with 5-year follow-up from Episealer®
- Directed share issue executed, raising SEK 159 million – funding until 2025 secured
”We are currently seeing high activity across the business with several initiatives ongoing within our commercialisation, clinical activities and product development. As already communicated, we experienced certain COVID-19 related effects during the quarter that we cannot disregard, but all in all we are taking important steps in the right direction, as we continuously are adding new customers, geographies, products and data, and we have secured funding until mid-2025”, says Pål Ryfors, CEO Episurf Medical.
Third quarter 2021 compared to 2020, Group
- Gross order intake amounted to SEK 1.6m (1.8).
- Order book amounted to SEK 1.4m (1.6)
- Group net sales SEK 1.5m (1.5)
- Loss for the period amounted to SEK -15.9m (-15.4)
- Earnings per share amounted to SEK -0.07 (-0.08)
First nine months 2021 compared to 2020, Group
- Gross order intake amounted to SEK 5.2m (4.3) an increase of 21%
- Group net sales increased by 46% to SEK 5.1m (3.5)
- Loss for the period amounted to SEK -50.4m (-47.7)
- Earnings per share amounted to SEK -0.23 (-0.32)
Significant events during the third quarter
- Results from prospective multicentre study with 5-7 years’ follow-up of the first Swedish Episealer® Knee patients accepted for publication
- Results from first comparative study with the Episealer® Knee implant were accepted for publication
- Episurf Medical investigates the opportunities for launching an implant for the MTP joint in the US market
- Episurf Medical announced additions to the European sales force and Patrick Jamnik to head US business
- Episurf Medical provided an update on the project Episealer® Patellofemoral System for the US market
- Episealer® Talus: Case report with 5-years’ follow-up data were accepted for publication
- European multicentre study were initiated for 5 years’ follow-up of Episealer® Talus patients
Significant events after the third quarter
- Episurf Medical carries out a directed share issue of SEK 159m. Ilija Batljan enters as new large shareholder
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the </em></span>Swedish Securities Markets Act (2007:528)<span style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 29 October 2021.</em></span></p>
[HtmlContact:protected] => <p><strong><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">For more information, please contact:</span></span></span></strong></p>
<p><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif"><span style="font-size:10pt"><span><span style="font-family:arial,helvetica,sans-serif">Pål Ryfors, CEO, Episurf Medical</span></span></span><br>
Tel:<span style="font-size:10pt">+46 (0) 709 62 36 69</span><br>
<span style="font-size:10pt">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></span></span></span></p>
<p><span><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">Veronica Wallin, CFO, Episurf Medical</span></span></span></span><br>
<span><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">Tel:</span></span></span></span><span><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">+46 (0) 700 37 48 95</span></span></span></span><br>
<span style="font-size:10pt"><span><span style="font-family:arial,helvetica,sans-serif">Email: </span></span></span><a href="mailto:pal.ryfors@episurf.com"><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">veronica.wallin@episurf.com</span></span></span></a></p>
[HtmlTitle:protected] => <h1 style="line-height:120%;"><strong>Interim Report 1 July – 30 September 2021</strong></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] =>
· Strategy updated to include two products targeting 510(k)-approval
· Published data from first comparative study and first study with 5-year follow-up from Episealer®
· Directed share issue executed, raising SEK 159 million – funding until 2025 secured
”We are currently seeing high activity across the business with several initiatives ongoing within our commercialisation, clinical activities and product development. As already communicated, we experienced certain COVID-19 related effects during the quarter that we cannot disregard, but all in all we are taking important steps in the right direction, as we continuously are adding new customers, geographies, products and data, and we have secured funding until mid-2025”, says Pål Ryfors, CEO Episurf Medical.
Third quarter 2021 compared to 2020, Group
· Gross order intake amounted to SEK 1.6m (1.8).
· Order book amounted to SEK 1.4m (1.6)
· Group net sales SEK 1.5m (1.5)
· Loss for the period amounted to SEK -15.9m (-15.4)
· Earnings per share amounted to SEK -0.07 (-0.08)
First nine months 2021 compared to 2020, Group
· Gross order intake amounted to SEK 5.2m (4.3) an increase of 21%
· Group net sales increased by 46% to SEK 5.1m (3.5)
· Loss for the period amounted to SEK -50.4m (-47.7)
· Earnings per share amounted to SEK -0.23 (-0.32)
Significant events during the third quarter
· Results from prospective multicentre study with 5-7 years’ follow-up of the first Swedish Episealer® Knee patients accepted for publication
· Results from first comparative study with the Episealer® Knee implant were accepted for publication
· Episurf Medical investigates the opportunities for launching an implant for the MTP joint in the US market
· Episurf Medical announced additions to the European sales force and Patrick Jamnik to head US business
· Episurf Medical provided an update on the project Episealer® Patellofemoral System for the US market
· Episealer® Talus: Case report with 5-years’ follow-up data were accepted for publication
· European multicentre study were initiated for 5 years’ follow-up of Episealer® Talus patients
Significant events after the third quarter
· Episurf Medical carries out a directed share issue of SEK 159m. Ilija Batljan enters as new large shareholder
[HtmlBody:protected] => <ul style="font-family:arial,helvetica,sans-serif; font-size:10pt">
<li style="; ;"><span><strong><span style="color:#375f74">Strategy updated to include two products targeting 510(k)-approval</span></strong></span></li>
<li style="; ;"><span><strong><span style="color:#375f74">Published data from first comparative study and first study with 5-year follow-up from Episealer®</span></strong></span></li>
<li style="; ;"><span><strong><span style="color:#375f74">Directed share issue executed, raising SEK 159 million – funding until 2025 secured</span></strong></span></li>
</ul>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;;margin-top:12px"><span><em>”We are currently seeing high activity across the business with several initiatives ongoing within our commercialisation, clinical activities and product development. As already communicated, we experienced certain COVID-19 related effects during the quarter that we cannot disregard, but all in all we are taking important steps in the right direction, as we continuously are adding new customers, geographies, products and data, and we have secured funding until mid-2025”, </em>says Pål Ryfors, CEO Episurf Medical. </span></p>
<p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span><span style="page:WordSection1"><span><strong><span><span style="color:#375f74">Third quarter 2021 compared to 2020, Group </span></span></strong></span></span></span></p>
<ul style="font-family:arial,helvetica,sans-serif; font-size:10pt">
<li style="; ;"><span><span style="page:WordSection1">Gross order intake amounted to SEK 1.6m (1.8). </span></span></li>
<li style="; ;"><span><span style="page:WordSection1">Order book amounted to SEK 1.4m (1.6)</span></span></li>
<li style="; ;"><span><span style="page:WordSection1">Group net sales SEK 1.5m (1.5)</span></span></li>
<li style="; ;"><span><span style="page:WordSection1">Loss for the period amounted to SEK -15.9m (-15.4) </span></span></li>
<li style="; ;"><span><span style="page:WordSection1">Earnings per share amounted to SEK -0.07 (-0.08)</span></span></li>
</ul>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span><span style="page:WordSection1"><strong><span style="color:#375f74">First nine months 2021 compared to 2020, Group</span></strong></span></span></p>
<ul style="font-family:arial,helvetica,sans-serif; font-size:10pt">
<li style="; ;"><span><span style="page:WordSection1">Gross order intake amounted to SEK 5.2m (4.3) an increase of 21% </span></span></li>
<li style="; ;"><span><span style="page:WordSection1">Group net sales increased by 46% to SEK 5.1m (3.5)</span></span></li>
<li style="; ;"><span><span style="page:WordSection1">Loss for the period amounted to SEK -50.4m (-47.7)</span></span></li>
<li style="; ;"><span><span style="page:WordSection1">Earnings per share amounted to SEK -0.23 (-0.32)</span></span></li>
</ul>
<p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span><span><strong><span><span style="color:#375f74">Significant events during the third quarter</span></span></strong> </span></span></p>
<ul style="font-family:arial,helvetica,sans-serif; font-size:10pt">
<li style="; ;"><span>Results from prospective multicentre study with 5-7 years’ follow-up of the first Swedish Episealer® Knee patients accepted for publication</span></li>
<li style="; ;"><span>Results from first comparative study with the Episealer® Knee implant were accepted for publication</span></li>
<li style="; ;"><span>Episurf Medical investigates the opportunities for launching an implant for the MTP joint in the US market</span></li>
<li style="; ;"><span>Episurf Medical announced additions to the European sales force and Patrick Jamnik to head US business</span></li>
<li style="; ;"><span>Episurf Medical provided an update on the project Episealer® Patellofemoral System for the US market</span></li>
<li style="; ;"><span>Episealer® Talus: Case report with 5-years’ follow-up data were accepted for publication</span></li>
<li style="; ;"><span>European multicentre study were initiated for 5 years’ follow-up of Episealer® Talus patients</span></li>
</ul>
<p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span><span><strong><span><span style="color:#375f74">Significant events after the third quarter</span></span></strong></span></span></p>
<ul style="font-family:arial,helvetica,sans-serif; font-size:10pt">
<li style="; ;"><span>Episurf Medical carries out a directed share issue of SEK 159m. Ilija Batljan enters as new large shareholder</span></li>
</ul>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => R3
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 153
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 12311
)
[4] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 29 October 2021.
[Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/3443081/1488359.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Q3 2021 Interim Report
[Description:protected] => Q3 2021 Interim Report
[CreateDate:protected] => 2021-10-29T06:30:19.527Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 4102629
[EncryptedId:protected] => 5F21F448E0968D7D
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2021-10-29T06:30:00Z
[LastChangeDate:protected] => 2021-10-29T06:30:19.51Z
[Title:protected] => Interim Report 1 July – 30 September 2021
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => RPT
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/interim-report-1-july---30-september-2021,c3443081
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)